Immunology of stiff person syndrome and other GAD-associated neurological disorders

Expert Review of Clinical Immunology

Volumn 9, Issue 11, 2013, Pages 1043-1053

  Alexopoulos, Harry ^a   Dalakas, Marinos C ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

autoantibodies; autoimmunity; cerebellar ataxia; epilepsy; GABA; GAD; limbic encephalitis; stiff person syndrome

Indexed keywords

4 AMINOBUTYRIC ACID; AUTOANTIBODY; AUTOANTIGEN; GLUTAMATE DECARBOXYLASE; GLYCINE RECEPTOR;

ANTIBODY TITER; AUTOIMMUNITY; CEREBELLAR ATAXIA; CLINICAL TRIAL (TOPIC); DISEASE SEVERITY; ENZYME ASSAY; EPILEPSY; EYE MOVEMENT DISORDER; GABAERGIC TRANSMISSION; HUMAN; IMMUNOLOGY; IN VITRO STUDY; NEUROLOGIC DISEASE; NEURONAL CEROID LIPOFUSCINOSIS; NONHUMAN; NYSTAGMUS; PARANEOPLASTIC NEUROPATHY; PATHOGENICITY; PATHOPHYSIOLOGY; REVIEW; STIFF MAN SYNDROME; SYMPTOMATOLOGY; SYNAPSE; SYNAPTIC TRANSMISSION; T LYMPHOCYTE;

ANIMALS; AUTOANTIBODIES; AUTOANTIGENS; AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM; BIOLOGICAL MARKERS; DISEASE MODELS, ANIMAL; ELECTRICAL SYNAPSES; GAMMA-AMINOBUTYRIC ACID; GLUTAMATE DECARBOXYLASE; HUMANS; LIMBIC ENCEPHALITIS; NERVOUS SYSTEM DISEASES; PROGNOSIS; STIFF-PERSON SYNDROME; SYNDROME;

EID: 84887264129     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2013.845527     Document Type: Review

References (93)

1. Solimena M, Folli F, Denis-Donini S et al. Autoantibodies to glutamic acid decarboxylase in a patient with stiff-man syndrome, epilepsy, and type I diabetes mellitus. N. Engl. J. Med. 318(16), 1012-1020 (1988).
2. Honnorat J, Saiz A, Giometto B et al. Cerebellar ataxia with anti-glutamic acid decarboxylase antibodies: study of 14 patients. Arch. Neurol. 58(2), 225-230 (2001).
3. Giometto B, Miotto D, Faresin F, Argentiero V, Scaravilli T, Tavolato B. Anti-gabaergic neuron autoantibodies in a patient with stiff-man syndrome and ataxia. J. Neurol. Sci. 143(1-2), 57-59 (1996).
4. Peltola J, Kulmala P, Isojarvi J et al. Autoantibodies to glutamic acid decarboxylase in patients with therapy-resistant epilepsy. Neurology 55(1), 46-50 (2000).
5. Malter MP, Helmstaedter C, Urbach H, Vincent A, Bien CG. Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis. Ann. Neurol. 67(4), 470-478 (2010).
6. Moss SJ, Smart TG. Constructing inhibitory synapses. Nat. Rev. Neurosci. 2(4), 240-250 (2001).
7. Butler MH, Solimena M, Dirkx R, Jr., Hayday A, De Camilli P. Identification of a dominant epitope of glutamic acid decarboxylase (GAD-65) recognized by autoantibodies in stiff-man syndrome. J. Exp. Med. 178(6), 2097-2106 (1993).
8. Roth FC, Draguhn A. GABA metabolism and transport: effects on synaptic efficacy. Neural. Plast. 2012, 805830.
9. Fenalti G, Buckle AM. Structural biology of the GAD autoantigen. Autoimmun. Rev. 9(3), 148-152 (2010).
10. Reetz A, Solimena M, Matteoli M, Folli F, Takei K, De Camilli P. GABA and pancreatic beta-cells: colocalization of glutamic acid decarboxylase (GAD) and GABA with synaptic-like microvesicles suggests their role in GABA storage and secretion. EMBO J. 10(5), 1275-1284 (1991).
11. Dalakas MC, Fujii M, Li M, McElroy B. The clinical spectrum of anti-GAD antibody-positive patients with stiff-person syndrome. Neurology 55(10), 1531-1535 (2000).
12. Alexopoulos H, Dalakas MC. A critical update on the immunopathogenesis of Stiff Person Syndrome. Eur. J. Clin. Invest. 40(11), 1018-1025 (2010).
13. Ameli R, Snow J, Rakocevic G, Dalakas MC. A neuropsychological assessment of phobias in patients with stiff person syndrome. Neurology 64(11), 1961-1963 (2005).
14. Meinck HM, Ricker K, Conrad B. The stiff-man syndrome: new pathophysiological aspects from abnormal exteroceptive reflexes and the response to clomipramine, clonidine, and tizanidine. J. Neurol. Neurosurg. Psychiatry 47(3), 280-287 (1984).
15. Sandbrink F, Syed NA, Fujii MD, Dalakas MC, Floeter MK. Motor cortex excitability in stiff-person syndrome. Brain 123 (Pt 11), 2231-2239 (2000).
16. Levy LM, Dalakas MC, Floeter MK. The stiff-person syndrome: an autoimmune disorder affecting neurotransmission of gamma-aminobutyric acid. Ann. Intern. Med. 131(7), 522-530 (1999).
17. McKeon A, Robinson MT, McEvoy KM et al. Stiff-man syndrome and variants: clinical course, treatments, and outcomes. Arch. Neurol. 69(2), 230-238 (2012).
18. Skorstad G, Hestvik AL, Torjesen P et al. GAD65 IgG autoantibodies in stiff person syndrome: clonality, avidity and persistence. Eur. J. Neurol. 15(9), 973-980 (2008).
19. Murinson BB. Stiff-person syndrome. Neurologist 10(3), 131-137 (2004).
20. Dalakas MC, Li M, Fujii M, Jacobowitz DM. Stiff person syndrome: quantification, specificity, and intrathecal synthesis of GAD65 antibodies. Neurology 57(5), 780-784 (2001).
21. Raju R, Rakocevic G, Chen Z et al. Autoimmunity to GABAA-receptor- associated protein in stiff-person syndrome. Brain 129(Pt 12), 3270-3276 (2006).
22. Chen L, Wang H, Vicini S, Olsen RW. The gamma-aminobutyric acid type A (GABAA) receptor-associated protein (GABARAP) promotes GABAA receptor clustering and modulates the channel kinetics. Proc. Natl Acad. Sci. USA 97(21), 11557-11562 (2000).
23. McKeon A, Martinez-Hernandez E, Lancaster E et al. Glycine receptor autoimmune spectrum with stiff-man syndrome phenotype. JAMA Neurol. 70(1), 44-50 (2013).
24. Mas N, Saiz A, Leite MI et al. Antiglycine-receptor encephalomyelitis with rigidity. J. Neurol. Neurosurg. Psychiatry 82(12), 1399-1401 (2011).
25. Iizuka T, Leite MI, Lang B et al. Glycine receptor antibodies are detected in progressive encephalomyelitis with rigidity and myoclonus (PERM) but not in saccadic oscillations. J. Neurol. 259(8), 1566-1573 (2012).
26. Davies JS, Chung SK, Thomas RH et al. The glycinergic system in human startle disease: a genetic screening approach. Front. Mol. Neurosci. 3, 8 (2010).
27. De Camilli P, Thomas A, Cofiell R et al. The synaptic vesicle-associated protein amphiphysin is the 128-kD autoantigen of Stiff-Man syndrome with breast cancer. J. Exp. Med. 178(6), 2219-2223 (1993).
28. Folli F, Solimena M, Cofiell R et al. Autoantibodies to a 128-kd synaptic protein in three women with the stiff-man syndrome and breast cancer. N. Engl. J. Med. 328(8), 546-551 (1993).
29. Butler MH, Hayashi A, Ohkoshi N et al. Autoimmunity to gephyrin in Stiff-Man syndrome. Neuron 26(2), 307-312 (2000).
30. Dalakas MC. Progress and stiff challenges in understanding the role of GAD-antibodies in stiff-person syndrome. Exp. Neurol. 247, 303-307 (2013).
31. Vincent A, Bien CG, Irani SR, Waters P. Autoantibodies associated with diseases of the CNS: new developments and future challenges. Lancet Neurol. 10(8), 759-772 (2011).
32. Vincent A, Leite MI. Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis. Curr. Opin. Neurol. 18(5), 519-525 (2005).
33. Solimena M, Butler MH, De Camilli P. GAD, diabetes, and Stiff-Man syndrome: some progress and more questions. J. Endocrinol. Invest. 17(7), 509-520 (1994).
34. Saiz A, Blanco Y, Sabater L et al. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain 131(Pt 10), 2553-2563 (2008).
35. Kim J, Namchuk M, Bugawan T et al. Higher autoantibody levels and recognition of a linear NH2-terminal epitope in the autoantigen GAD65, distinguish stiff-man syndrome from insulin-dependent diabetes mellitus. J. Exp. Med. 180(2), 595-606 (1994).
36. Burbelo PD, Groot S, Dalakas MC, Iadarola MJ. High definition profiling of autoantibodies to glutamic acid decarboxylases GAD65/GAD67 in stiff-person syndrome. Biochem. Biophys. Res. Commun. 366(1), 1-7 (2008).
37. Pugliese A, Brown D, Garza D et al. Self-antigen-presenting cells expressing diabetes-associated autoantigens exist in both thymus and peripheral lymphoid organs. J. Clin. Invest. 107(5), 555-564 (2001).
38. Hassin-Baer S, Kirson ED, Shulman L et al. Stiff-person syndrome following West Nile fever. Arch. Neurol. 61(6), 938-941 (2004).
39. Burns TM. A step forward for stiff-person syndrome. Lancet 365(9468), 1365-1367 (2005).
40. Koerner C, Wieland B, Richter W, Meinck HM. Stiff-person syndromes: motor cortex hyperexcitability correlates with anti-GAD autoimmunity. Neurology 62(8), 1357-1362 (2004).
41. Floeter MK, Valls-Sole J, Toro C, Jacobowitz D, Hallett M. Physiologic studies of spinal inhibitory circuits in patients with stiff-person syndrome. Neurology 51(1), 85-93 (1998).
42. Levy LM, Levy-Reis I, Fujii M, Dalakas MC. Brain gamma-aminobutyric acid changes in stiff-person syndrome. Arch. Neurol. 62(6), 970-974 (2005).
43. Dinkel K, Meinck HM, Jury KM, Karges W, Richter W. Inhibition of gamma-aminobutyric acid synthesis by glutamic acid decarboxylase autoantibodies in stiff-man syndrome. Ann. Neurol. 44(2), 194-201 (1998).
44. Raju R, Foote J, Banga JP et al. Analysis of GAD65 autoantibodies in Stiff-Person syndrome patients. J. Immunol. 175(11), 7755-7762 (2005).
45. Jarius S, Stich O, Speck J et al. Qualitative and quantitative evidence of anti-glutamic acid decarboxylase-specific intrathecal antibody synthesis in patients with stiff person syndrome. J. Neuroimmunol. 229(1-2), 219-224 (2010).
46. Rakocevic G, Raju R, Dalakas MC. Anti-glutamic acid decarboxylase antibodies in the serum and cerebrospinal fluid of patients with stiff-person syndrome: correlation with clinical severity. Arch. Neurol. 61(6), 902-904 (2004).
47. Nemni R, Caniatti LM, Gironi M, Bazzigaluppi E, De Grandis D. Stiff person syndrome does not always occur with maternal passive transfer of GAD65 antibodies. Neurology 62(11), 2101-2102 (2004).
48. Dalakas MC. Stiff person syndrome: advances in pathogenesis and therapeutic interventions. Curr. Treat. Options Neurol. 11(2), 102-110 (2009).
49. Vincent A. Stiff, twitchy or wobbly: are GAD antibodies pathogenic? Brain 131(Pt 10), 2536-2537 (2008).
50. Manto MU, Laute MA, Aguera M, Rogemond V, Pandolfo M, Honnorat J. Effects of anti-glutamic acid decarboxylase antibodies associated with neurological diseases. Ann. Neurol. 61(6), 544-551 (2007).
51. Manto MU, Hampe CS, Rogemond V, Honnorat J. Respective implications of glutamate decarboxylase antibodies in stiff person syndrome and cerebellar ataxia. Orphanet. J. Rare. Dis. 6, 3 (2011).
52. Geis C, Weishaupt A, Grunewald B et al. Human stiff-person syndrome IgG induces anxious behavior in rats. PLoS ONE 6(2), e16775 (2011).
53. Hansen N, Grunewald B, Weishaupt A et al. Human Stiff person syndrome IgG-containing high-titer anti-GAD65 autoantibodies induce motor dysfunction in rats. Exp. Neurol. 239, 202-209 (2013).
54. Chang T, Alexopoulos H, McMenamin M et al. Neuronal Surface and Glutamic Acid Decarboxylase Autoantibodies in Nonparaneoplastic Stiff Person Syndrome. JAMA Neurol. 70(9), 1140-1149 (2013).
55. Sommer C, Weishaupt A, Brinkhoff J et al. Paraneoplastic stiff-person syndrome: passive transfer to rats by means of IgG antibodies to amphiphysin. Lancet 365(9468), 1406-1411 (2005).
56. Geis C, Weishaupt A, Hallermann S et al. Stiff person syndrome-associated autoantibodies to amphiphysin mediate reduced GABAergic inhibition. Brain 133(11), 3166-3180 (2010).
57. Geis C, Beck M, Jablonka S et al. Stiff person syndrome associated anti-amphiphysin antibodies reduce GABA associated [Ca(2+)]i rise in embryonic motoneurons. Neurobiol. Dis. 36(1), 191-199 (2009).
58. Geis C, Grunewald B, Weishaupt A et al. Human IgG directed against amphiphysin induces anxiety behavior in a rat model after intrathecal passive transfer. J. Neural. Transm. 119(8), 981-985 (2012).
59. Lohmann T, Hawa M, Leslie RD, Lane R, Picard J, Londei M. Immune reactivity to glutamic acid decarboxylase 65 in stiffman syndrome and type 1 diabetes mellitus. Lancet 356(9223), 31-35 (2000).
60. Lohmann T, Londei M, Hawa M, Leslie RD. Humoral and cellular autoimmune responses in stiff person syndrome. Ann. N. Y. Acad. Sci. 998, 215-222 (2003).
61. Skorstad G, Hestvik AL, Vartdal F, Holmoy T. Cerebrospinal fluid T cell responses against glutamic acid decarboxylase 65 in patients with stiff person syndrome. J. Autoimmun. 32(1), 24-32 (2009).
62. Burton AR, Baquet Z, Eisenbarth GS et al. Central nervous system destruction mediated by glutamic acid decarboxylase-specific CD4+ T cells. J. Immunol. 184(9), 4863-4870(2010).
63. Holmoy T, Skorstad G, Roste LS, Scheie D, Alvik K. Stiff person syndrome associated with lower motor neuron disease and infiltration of cytotoxic T cells in the spinal cord. Clin. Neurol. Neurosurg. 111(8), 708-712 (2009).
64. Witherick J, Highley JR, Hadjivassiliou M. Pathological findings in a case of stiff person syndrome with anti-GAD antibodies. Mov. Disord. 26(11), 2138-2139(2011).
65. Rakocevic G, Raju R, Semino-Mora C, Dalakas MC. Stiff person syndrome with cerebellar disease and high-titer anti-GAD antibodies. Neurology 67(6), 1068-1070 (2006).
66. Kono S, Miyajima H, Sugimoto M, Suzuki Y, Takahashi Y, Hishida A. Stiff-person syndrome associated with cerebellar ataxia and high glutamic acid decarboxylase antibody titer. Intern. Med. 40(9), 968-971 (2001).
67. Costa M, Saiz A, Casamitjana R et al. T-cell reactivity to glutamic acid decarboxylase in stiff-man syndrome and cerebellar ataxia associated with polyendocrine autoimmunity. Clin. Exp. Immunol. 129(3), 471-478 (2002).
68. Takenoshita H, Shizuka-Ikeda M, Mitoma H et al. Presynaptic inhibition of cerebellar GABAergic transmission by glutamate decarboxylase autoantibodies in progressive cerebellar ataxia. J Neurol Neurosurg Psychiatry 70(3), 386-389 (2001).
69. Hampe CS, Petrosini L, De Bartolo P et al. Monoclonal antibodies to 65kDa glutamate decarboxylase induce epitope specific effects on motor and cognitive functions in rats. Orphanet. J. Rare Dis. 8, 82 (2013).
70. Quek AM, Britton JW, McKeon A et al. Autoimmune epilepsy: clinical characteristics and response to immunotherapy. Arch. Neurol. 69(5), 582-593 (2012).
71. Vianello M, Giometto B, Vassanelli S, Canato M, Betterle C, Mucignat C. Peculiar labeling of cultured hippocampal neurons by different sera harboring anti-glutamic acid decarboxylase autoantibodies (GAD-Ab). Exp. Neurol. 202(2), 514-518 (2006).
72. Vianello M, Bisson G, Dal Maschio M et al. Increased spontaneous activity of a network of hippocampal neurons in culture caused by suppression of inhibitory potentials mediated by anti-gad antibodies. Autoimmunity 41(1), 66-73 (2008).
73. Stagg CJ, Lang B, Best JG et al. Autoantibodies to glutamic acid decarboxylase in patients with epilepsy are associated with low cortical GABA levels. Epilepsia 51(9), 1898-1901 (2010).
74. Brenner T, Sills GJ, Hart Y et al. Prevalence of neurologic autoantibodies in cohorts of patients with new and established epilepsy. Epilepsia 54(6), 1028-1035 (2013).
75. Falip M, Carreno M, Miro J et al. Prevalence and immunological spectrum of temporal lobe epilepsy with glutamic acid decarboxylase antibodies. Eur. J. Neurol. 19(6), 827-833 (2012).
76. Bien CG, Vincent A, Barnett MH et al. Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain 135(Pt 5), 1622-1638 (2012).
77. Tilikete C, Vighetto A, Trouillas P, Honnorat J. Potential role of anti-GAD antibodies in abnormal eye movements. Ann. N. Y. Acad. Sci. 1039, 446-454 (2005).
78. Antonini G, Nemni R, Giubilei F et al. Autoantibodies to glutamic acid decarboxylase in downbeat nystagmus. J. Neurol. Neurosurg. Psychiatry 74(7), 998-999 (2003).
79. Ramirez-Montealegre D, Chattopadhyay S, Curran TM et al. Autoimmunity to glutamic acid decarboxylase in the neurodegenerative disorder Batten disease. Neurology 64(4), 743-745 (2005).
80. Pearce DA, Atkinson M, Tagle DA. Glutamic acid decarboxylase autoimmunity in Batten disease and other disorders. Neurology 63(11), 2001-2005 (2004).
81. Vasconcelos OM, Dalakas MC. Stiff-person Syndrome. Curr. Treat. Options Neurol. 5(1), 79-90 (2003).
82. Dalakas MC, Fujii M, Li M, Lutfi B, Kyhos J, McElroy B. High-dose intravenous immune globulin for stiff-person syndrome. N. Engl. J. Med. 345(26), 1870-1876 (2001).
83. Meinck HM, Thompson PD. Stiff man syndrome and related conditions. Mov. Disord. 17(5), 853-866 (2002).
84. Hao W, Davis C, Hirsch IB et al. Plasmapheresis and immunosuppression in stiff-man syndrome with type 1 diabetes: a 2-year study. J. Neurol. 246(8), 731-735 (1999).
85. Baker MR, Das M, Isaacs J, Fawcett PR, Bates D. Treatment of stiff person syndrome with rituximab. J. Neurol. Neurosurg. Psychiatry 76(7), 999-1001 (2005).
86. Dalakas MC, Rakocevic G, Dambrosia J, McElroy B. A double-blind, placebo-controlled study of rituximab in patients with stiff-person syndrome (SPS). Ann. Neurol. 66, S20-S20(Suppl.) 13 (2009).
87. Rizzi M, Knoth R, Hampe CS et al. Long-lived plasma cells and memory B cells produce pathogenic anti-GAD65 autoantibodies in Stiff Person Syndrome. PLoS ONE 5(5), e10838 (2010).
88. Dalakas MC. Invited article: inhibition of B cell functions: implications for neurology. Neurology 70(23), 2252-2260 (2008).
89. Dalakas MC. Advances in the pathogenesis and treatment of patients with stiff person syndrome. Curr. Neurol. Neurosci. Rep. 8(1), 48-55 (2008).
90. Peyron C, Faraco J, Rogers W et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat. Med. 6(9), 991-997 (2000).
91. Dalakas MC. Biologics and other novel approaches as new therapeutic options in myasthenia gravis: a view to the future. Ann. N. Y. Acad. Sci. 1274, 1-8 (2013).
92. Dalakas MC. Novel future therapeutic options in Myasthenia Gravis. Autoimmun. Rev. 12(9), 936-941 (2013).
93. Oak S, Gilliam LK, Landin-Olsson M et al. The lack of anti-idiotypic antibodies, not the presence of the corresponding autoantibodies to glutamate decarboxylase, defines type 1 diabetes. Proc. Natl Acad. Sci. USA 105(14), 5471-5476 (2008).